15% of the worldwide population suffers from hearing deficiencies, among which tinnitus is a predominant pathology. This is the result from ageing population, noisy lifestyle, infections, and more than 200 ototoxic drugs on the market.
Tinnitus is one of the most common hearing disorder. It can be perceived as a continuous or intermittent sound, which can be constant with variable intensities. Around 10% of the population suffers from it, which can be associated with hearing loss. Tinnitus can have several disabling consequences on one’s quality of life, among those stress, sleep disturbances, anxiety, pain, depression…
Today, there is no pharmaceutical treatment on the market to treat tinnitus. Some “management options” are available to help patient deal with tinnitus, such as analgesic and neuromodulator drugs, “sound masking” therapies, cognitive therapies, hearing aids and nutraceuticals.
Several targets are described at different levels of the auditory pathway, which are potential targets for the development of tinnitus therapies.
Watch this 30 min presentation by Sylvie Pucheu, CSO of CILcare, to understand more about preclinical models offered by CILcare:
Our member CILCare is a world renowned CRO with leading expertise in hearing disorders. They support pharmaceutical companies, biotechs and academics in their preclinical research for new therapies treating hearing loss, tinnitus and otitis.
Are you working on a drug discovery program to develop tinnitus treatment? Visit our partner CILcare’s page to learn more on how we can help you with your preclinical research programs.
Please contact us for any additional information and we will gladly come back to you. We can also set up a dedicated meeting between you and our experts to discuss our CRO services and your research needs.